13 New Drugs Pass Muster At The EMA, Dexamethasone Withdrawal Explained

New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.

ApproveOnKeyboard_1200x675 — Numerous new drugs are poised to be approved in the EU • Source: Shutterstock

Byfavo (remimazolam), Paion’s drug for procedural sedation, and Ontozry (cenobamate), Arvelle Therapeutics’ epilepsy treatment, are among the 13 new drugs that the European Medicines Agency has said should be granted pan-EU marketing authorization.

Byfavo is an ultra-short-acting intravenous benzodiazepine that is approved for procedural sedation in the US and China and for general...